\nOmnicell, Inc. (NASDAQ:OMCL) (\u201cOmnicell\u201d or the \u201cCompany\u201d), a leader in transforming the pharmacy care delivery model, today announced it has increased its number of board seats from 9 to 10, and has appointed Kaushik \u201cBobby\u201d Ghoshal to fill the newest seat as an independent director of Omnicell\u2019s Board of Directors, effective immediately.<\/p>\n
This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230711576271\/en\/<\/a><\/p>\n Omnicell Appoints Bobby Ghoshal to Board of Directors (Photo: Business Wire)<\/p>\n<\/div>\n \nMr. Ghoshal is an established technology leader who brings more than 30 years of experience across multiple industries including finance, semiconductors, and healthcare. In Mr. Ghoshal\u2019s current role as President of SaaS for ResMed, Inc. (\u201cResMed\u201d), he leads the Company\u2019s global software business and is responsible for the vision, strategy, and day-to-day operations of the Company\u2019s rapidly expanding SaaS portfolio. Prior to this, he served as ResMed\u2019s Chief Technology Officer. He has also served as Chief Operating Officer of Brightree LLC, a ResMed-owned provider of cloud-based SaaS for out-of-hospital care.<\/p>\n \n\u201cWe are delighted to welcome Bobby to Omnicell\u2019s Board of Directors,\u201d said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. \u201cBobby has an impressive track record leading high-performance teams in software products, digital and business transformation, information security, data analytics, and artificial intelligence and machine learning. We look forward to benefitting from his unique perspective at the intersection of SaaS and healthcare, as we continue to work to transform the pharmacy care delivery model and deliver value for our stakeholders, our healthcare partners, and their patients.\u201d<\/p>\n \n\u201cEvery day, customers rely on Omnicell to deliver mission-critical medication management solutions and I am honored to join the Company\u2019s Board,\u201d said Mr. Ghoshal. \u201cI have been impressed with Omnicell\u2019s progress toward realizing the industry vision of the Autonomous Pharmacy and am excited to have the opportunity to take part in helping the Company achieve its goals. I look forward to leveraging my background in SaaS and healthcare to build on Omnicell\u2019s strong foundation and help deliver on its mission to improve patient outcomes.\u201d<\/p>\n \nThe addition of Mr. Ghoshal to Omnicell\u2019s Board is part of the Board\u2019s ongoing refreshment process, which has resulted in the addition of five new directors in the last four years. In connection with his appointment, Mr. Ghoshal will join the Board\u2019s Corporate Governance Committee. The Board now comprises 10 directors, 9 of whom are independent and all of whom bring a broad range of skills and experience that enhance the Board\u2019s ability to effectively fulfill its governance and oversight responsibilities.<\/p>\n About Omnicell<\/b><\/p>\n \nSince 1992, Omnicell has been committed to transforming the pharmacy care delivery model in an effort to optimize financial and clinical outcomes across all settings of care. Through a comprehensive portfolio of automation and advanced services, Omnicell is uniquely positioned to address evolving healthcare challenges, connect settings of care, and streamline the medication management process. Healthcare facilities worldwide partner with Omnicell to help increase operational efficiency, reduce medication errors, improve patient safety, and enhance patient engagement and adherence, helping to reduce costly hospital readmissions. To learn more, visit omnicell.com<\/a>.<\/p>\n \nFrom time to time, Omnicell may use the Company\u2019s investor relations website and other online social media channels, including its Twitter handle www.twitter.com\/omnicell<\/a>, LinkedIn page www.linkedin.com\/company\/omnicell<\/a>, and Facebook page www.facebook.com\/omnicellinc<\/a>, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (\u201cReg FD\u201d).<\/p>\n \nOMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nTo the extent any statements contained in this press release deal with information that is not historical, these statements are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201cgoals,\u201d \u201ctarget,\u201d \u201cestimate,\u201d \u201cseek,\u201d \u201cpredict,\u201d \u201cproject,\u201d and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell\u2019s control. Such statements include, but are not limited to, Omnicell\u2019s expectations regarding the director appointment and statements about Omnicell\u2019s strategy, plans, objectives, goals, vision, and expected benefits. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell\u2019s ability to recruit and retain skilled and motivated personnel, (iii) Omnicell\u2019s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iv) risks related to Omnicell\u2019s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions, (v) risks related to failing to maintain expected service levels when providing our Advanced Services or retaining our Advanced Services customers, (vi) Omnicell\u2019s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (vii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, and (viii) other risks and uncertainties further described in the \u201cRisk Factors\u201d section of Omnicell\u2019s most recent Annual Report on Form 10-K, as well as in Omnicell\u2019s other reports filed with or furnished to the United States Securities and Exchange Commission (\u201cSEC\u201d), available at www.sec.gov<\/a>. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.<\/p>\n \nOMCL-E<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230711576271\/en\/<\/a><\/span><\/p>\n \nFor more information, contact:<\/p>\n \nKathleen Nemeth KEYWORDS:<\/b> United States North America Texas<\/p>\n INDUSTRY KEYWORDS:<\/b> Data Management Health Technology Hospitals Practice Management Software Pharmaceutical<\/p>\n![\"Omnicell](\"https:\/\/mms.businesswire.com\/media\/20230711576271\/en\/1837911\/4\/profile-bobby-ghoshal-v1.jpg\")
<\/p>\n<\/p>\n
\n
Senior Vice President, Investor Relations
\n
Kathleen.Nemeth@omnicell.com
\n<\/a>
650-435-3318<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230711576271\/en\/770780\/3\/01_omnicell_lockup_horizontal_green_rgb.jpg\")
<\/td>\n<\/tr>\n![\"Photo\"](\"https:\/\/mms.businesswire.com\/media\/20230711576271\/en\/1837911\/3\/profile-bobby-ghoshal-v1.jpg\")
<\/td>\n<\/tr>\n